Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions

HER2-positive Metastatic Breast CancerOligometastatic Disease

Interventions

DRUG

Trastuzumab emtansine

SRT for metastatic foci

Trial Locations (1)

RECRUITING

N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg

All Listed Sponsors

lead

N.N. Petrov National Medical Research Center of Oncology

OTHER